The FDA accepted Bayer's sNDA and granted Priority Review to elinzanetant for vasomotor symptoms in women on endocrine therapy for HR+ breast cancer.
News|Articles|October 19, 2011
Video: Using Inhalers and Puffers in Asthma
A clinical nurse consultant demonstrates best practices for inhalers and puffers, with an emphasis on pediatric asthma patients.
Advertisement
A clinical nurse consultant demonstrates best practices for inhalers and puffers, with an emphasis on pediatric asthma patients.
Advertisement
Related to this article
The FDA has approved baricitinib for adolescents aged 12 and older with severe alopecia areata, marking the first systemic oral therapy cleared for this population.
Stroke incidence in adults aged 20–54 nearly doubled from 1993–1994 to 2020, driven largely by ischemic stroke, while 30-day fatality declined, according to new research.
The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes.
New research links type 2 diabetes and genetic risk to MASLD cirrhosis before 50, warning age-based fibrosis scores can miss severe disease.
FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.
A US laboratory study found that 29.5% of patients with Lyme antibodies were seropositive for at least 1 other tick-borne pathogen.
Lumateperone reduced acute mania symptoms by day 3 in a phase 3 bipolar 1 trial, according to Johnson & Johnson.
Advertisement
Advertisement
Trending on Patient Care Online
1
Beyond Semaglutide and Tirzepatide: The Next Wave of Obesity Medicines
2
FDA Grants Priority Review to Elinzanetant for VMS in HR+ Breast Cancer Patients on Endocrine Therapy
3
Safety, Dosing, and Drug Interactions for Dextromethorphan-Bupropion in Agitation
4
FDA Expands Baricitinib Approval to Adolescents With Severe Alopecia Areata
5